ESC Congress 2026: key results and trends

Evolocumab significantly reduced the risk of any MI by 36% compared with placebo (149 [5-Yr Kaplan-Meier, 2.7%] vs 229 [5-Yr Kaplan-Meier, 4.1%]; HR 0.64, 95% CI 0.52–0.79; p<0.0001).

Monotherapy produced a -36.4% LDL-C reduction versus placebo, with 67% and 48.5% achieving LDL-C <70 mg/dL and <55 mg/dL (placebo: 21.6% and 6.7%).

In patients with mild renal impairment, HbA1c was reduced by 0.51% vs. placebo (p<0.01).

Vutrisiran treatment was associated with 25% relative risk reduction of all AEs vs placebo in the overall study population (ARR: 0.75).

Overall, serious adverse events occurred in 1.5%, 2.5% and 1.7% of patients with baxdrostat 1 mg, 2 mg and placebo, respectively, in the low dose group, and 2.5%, 4.5% and 3.7% with baxdrostat 1 mg, 2 mg and placebo, respectively, in the standard dose group.

Corresponding mean changes in TGs were −52% (p=0.005), −68% (p=0.0007), and −68% (p=0.0007) for 30, 100, and 300 mg, respectively, versus +0.2% with pooled placebo.

Treatment-emergent adverse events (AE) were reported by 34 (94.4%) subjects in the HRS-7249 group and 8 (66.7%) subjects in the placebo group, most of which were mild in severity.

Treatment-emergent adverse events (TEAEs) were reported in 9 (100%), 8 (80.0%) and 6 (100%) of patients in the HRS-9057 15 mg, 30 mg, and tolvaptan groups, respectively.

The most common TEAEs in HRS-1301 group were increased white blood cell count (9.4%) and white blood cells urine positive (9.4%) in SAD, and decreased blood fibrinogen (12.1%), increased white blood cell count (9.1%) and increased bilirubin conjugated (9.1%) in MAD.